Literature DB >> 691003

Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.

H J Petersen, C K Nielsen, E Arrigoni-Martelli.   

Abstract

A variety of N-alkyl-N'-pyridyl-N"-cyanoguanidines III was prepared as potential bioisosteres of hypotensive N-alkyl-N'-pyridylthioureas Ia. Optimal activity of the N,N'-disubstituted cyanoguanidines III was assoicated with the presence of four to seven carbon branched alkyl and 3- or 4-pyridyl groups. Maximum potency was displayed by N-tert-pentyl-N'-3 pyridyl-N"-cyanoguanidine (20). This compound proved to be 200 times more potent than the corresponding thiourea in hypertensive rats and dogs. In comparison with guancydine, which is the de-3-pyridyl analogue of 20, a 150-fold increase of potency in spontaneously hypertensive rats was obtained with 20 and its tert-butyl analogue 19. The observed activity appears to be due to direct vascular relaxation. On a weight basis compounds 19, 20, 50, and 101 compared favorably with hydralazine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 691003     DOI: 10.1021/jm00206a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

Review 1.  Pharmacology of the potassium channel openers.

Authors:  G Edwards; A H Weston
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 2.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 3.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

5.  Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.

Authors:  A McBurney; P R Farrow; S Ainsworth; J W Ward
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

6.  Modifications by chronic intermittent hypoxia and drug treatment on skeletal muscle metabolism.

Authors:  O Pastoris; M Dossena; P Foppa; R Arnaboldi; A Gorini; R F Villa; G Benzi
Journal:  Neurochem Res       Date:  1995-02       Impact factor: 3.996

7.  Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.

Authors:  G Muiesan; R Fariello; M L Muiesan; O E Christensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator.

Authors:  E Arrigoni-Martelli; C K Nielsen; U B Olsen; H J Petersen
Journal:  Experientia       Date:  1980-04-15

10.  Maintenance of functional activity of human pulmonary arteries after cryopreservation.

Authors:  P Ellis; E Müller-Schweinitzer
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.